Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Myeloproliferative Disorders 6Carcinoma, Non-Small-Cell Lung 5Primary Myelofibrosis 4Hematologic Neoplasms 4Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Hodgkin Disease 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Thrombocytosis 1Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Polycythemia Vera 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma 1Liposarcoma, Myxoid 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Doxorubicin 17Cyclophosphamide 15Ifosfamide 11fludarabine 8Radiotherapy 8tazemetostat 4pembrolizumab 4pazopanib 4Gemcitabine 4pegfilgrastim 3cixutumumab 3Trabectedin 3Radiation 3Imatinib Mesylate 3Filgrastim 3Docetaxel 3Dacarbazine 3sargramostim 2liposomal doxorubicin 2fludarabine phosphate 2brostallicin 2aldesleukin 2X-Rays 2Sunitinib 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leukapheresis 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma, Synovial × itacitinib × Clear all
NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Fred Hutchinson Cancer Center

Phase 1 Terminated
27 enrolled
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡